Health Bill

Debate between Anna Dixon and Grahame Morris

Report stage & 3rd reading
Tuesday 8th September 2026 Commons Chamber

[Grahame Morris (Easington) (Lab)]

I am speaking today in support of new clauses 113 and 114, which stand in the name of the hon. Member for Westmorland and Lonsdale (Tim Farron) and to which I have added my name.

I say at the outset that I am in full support of this Government’s ambitions on cancer. I welcome the recent investment in radiotherapy equipment, and I sincerely want the national cancer plan, which was published in February, to succeed. But I speak as someone who worked in the health service, who is a cancer survivor and who has taken a particular interest in this issue, not least as vice chairman of the all-party parliamentary group on radiotherapy. It is in that capacity, and as a supporter of what the Government are trying to achieve, that I respectfully ask Ministers to accept one or both of these new clauses.

By way of brief explanation, new clause 113 requires the Secretary of State to publish and maintain a national framework of agreed metrics for radiotherapy, requires integrated care boards to report annually against those targets and requires a report to this House once a year. New clause 114 asks very straightforwardly for a single review of access to radiotherapy and radiotherapy waiting times to be laid before Parliament within six months.

[Anna Dixon (Shipley) (Lab)]

Does my hon. Friend agree that the ethnic inequalities we see in cancer outcomes and access to cancer treatment such as radiotherapy should also be included in the suggested review?

[Grahame Morris]

This is a huge issue that should concern everyone. I believe there is cross-party consensus on the issue of health inequalities and huge variation in access depending on which part of the country people live in. That is an absolutely valid point.

We know the international consensus is that around half of all cancer patients have an evidence-based indication for radiotherapy at some point in their treatment. We should be aware that here in the United Kingdom in 2021, the last date for which figures were available, only 35% of cancer patients received it as part of their primary treatment.